VRNA (Verona Pharma PLC) Net Profit

Corporate emblem and logo of veronapharma.com (VRNA)

Verona Pharma plc (VRNA) is implementing innovations for COPD therapy, banking on high margins and strong free cash flow. However, the business's success relies on the commercialization of a single drug and the decisions of insurers. The company's profit volume clearly demonstrates these market fluctuations, where -0.08 captures the current state of the parameter. Optimizing logistics routes and controlling raw material supplies should ensure the further stability of these indicators.

VRNA (Verona Pharma) Company Net Income history from 07/04/2022 to 10/18/2025

Financial and market metric breakdowns for Verona Pharma (VRNA)

- price and consensus price forecast:
Stock Quotes Verona Pharma Inc.|VRNA - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Verona Pharma Inc.|VRNA - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Verona Pharma|VRNA - Company Book Value|Market-to-Book Ratio veronapharma.com|VRNA - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Verona Pharma plc|VRNA - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Verona Pharma PLC|VRNA - Company Aggregate Debts|Debts to Book Value Verona Pharma Inc.|VRNA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Verona Pharma|Quick Liquidity veronapharma.com
- net income and valuation multiples indicators:
VRNA - Net Profit
Fundamental valuation:VRNA Verona Pharma Inc.
Flagship merchandise of Verona Pharma PLC

The indicator is calculated as the difference between total revenues and all operating and non-operating expenses. This metric determines the overall business efficiency, reflecting the issuer's ability to generate net cash flow. For Verona Pharma plc (VRNA), this is a critical marker given the costs of innovative research and development in the therapy of respiratory pathologies. Program diversification reduces risks, directly impacting the financial result. By analyzing the company's profit dynamics, an investor can assess the resilience of Verona Pharma plc (VRNA) to market cyclicality.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit jyongbio.com|Net Income LGND (Ligand)|AMRX (Amneal Pharmaceuticals, Inc.) - Final Profit|Company Net Income Perrigo Company PRGO|Alvotech Biopharmaceuticals (ALVO) - Company Net Income|LQDA: Net Income|glpg.com - Profit After Payment of Taxes|ANIP: Net Profit|MannKind Corp - Final Profit|AMPH (Amphastar) - Net Profit|Company Net Income Pacira Corp PCRX|Company Net Income ARS Pharmaceuticals (SPRY)|TBPH (theravance.com) - Final Profit|Aquestive Therapeutics, Inc. - Net Income|scPharmaceuticals, Inc. - Company Net Income|Tectonic - Net Profit|Company Net Income Tonix Pharmaceuticals Holding|sxtchina.com (SXTC) - Company Net Income|Eupraxia Pharmaceuticals Inc. - Final Profit|Company Net Income BioHarvest Sciences Inc.|Company Net Income Invizyne Technologies EXOZ|Company Net Income Oramed Pharmaceuticals (ORMP)|enterabio.com - Company Profit|Net Profit HYFT (MindWalk Holdings)|Net Profit abvcpharma.com ABVC|CPIX: Net Income|Final Profit QNTM (Quantum BioPharma Ltd.)|FibroGen Corp (FGEN) - Company Net Income|Profit After Tax TELO (Telomir Pharmaceuticals Corp)|RANI (Rani Therapeutics Holdings) - Net Profit|SNYR: Final Profit|Net Profit RLYB|Net Profit lexariabioscience.com (LEXX)|Company Net Income Pulmatrix Corp PULM|Final Profit PTHL|APM - Company Net Income|lyratherapeutics.com (LYRA) - Net Income|IBO: Net Profit|TNF Pharmaceuticals, Inc. (TNFA) - Net Profit|Net Income YCBD|PRFX: Final Profit|Company Net Income Altamira Therapeutics (CYTO)|LIPO: Profit After Tax|Company Net Income OptiNose OPTN|Pieris Pharmaceuticals Inc - Company Net Income|Procaps Group SA - Net Profit|Petros Pharma (PTPI) - Net Income|QLI (Qilian International) - Net Income|SLRN (acelyrin.com) - Company Net Income|Company Net Income TFF Pharmaceuticals, Inc.